PanTher TherapeuticsSeptember 10, 2025PanTher Completes First Cohort in Pancreatic Cancer Phase 1b Trial Ahead of Expectations
PanTher TherapeuticsJuly 8, 2025PanTher Initiates Phase 1b Clinical Trial of Absorbable, Long-Lasting, High-Dose Chemotherapy Patch for Pancreatic Cancer
PanTher TherapeuticsAugust 13, 2024PanTher Therapeutics Receives FDA Clearance of IND Application for Phase 1b Study of PTM-101 for the Localized Treatment of Pancreatic Cancer
PanTher TherapeuticsSeptember 1, 2022PanTher Therapeutics Awarded $14.2M from CPRIT to Advance Targeted, Localized and Sustained Cancer Treatment
PanTher TherapeuticsMay 31, 2022PanTher Therapeutics Secures Patent for Anticancer Drug-Eluting Stent
PanTher TherapeuticsOctober 15, 2021PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer
PanTher TherapeuticsAugust 4, 2021PanTher Therapeutics Receives Ethics Approval to Initiate Phase 1 Clinical Trial of PTM-101 in Australia; Announces Appointment of Chief Medical Officer; Establishes Clinical Advisory Board
PanTher TherapeuticsJune 17, 2021PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer
